PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension
Recruiting · NCT07131241 · Observational (researchers observe without assigning treatment) · Lead sponsor: First Affiliated Hospital of Fujian Medical University
View the official record on ClinicalTrials.gov →What this trial is about
Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality. Despite advances in diagnostics, risk stratification remains limited due to the disease's heterogeneity. This study aims to develop and validate a dynamic risk prediction model for PH by integrating multimodal data-including echocardiography, Cardiac MRI, PET-MR, ECG, biomarkers, and clinical features-using advanced machine learning algorithms. The study will establish a prospective cohort of PH patients to explore predictive markers, stratify prognosis, and provide a scientific basis for early warning and individualized management.
Who can take part
Inclusion criteria
- Adults aged 18 years or older
- Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography
- Provided written informed consent
Exclusion criteria
- Severe hepatic or renal insufficiency
- Malignancy under active treatment
- Severe infection
- Active autoimmune disease
- Major surgery within the past 3 months
- Pregnant or breastfeeding women
- Severe psychiatric disorder impairing ability to comply with the study protocol
Where it is running
1 location listed.
- The First Affiliated Hospital of Fujian Medical University - Fuzhou, Fujian, China